CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will sponsor a booth and showcase its groundbreaking cardiovascular solutions at the 2024 Onsite Employee Health Clinics Forum.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the successful completion of its System and Organization Controls (SOC) 2 Type I audit.
Cardio Diagnostics Holdings shares added more than 75% on Monday after positive results from a trial of the company's coronary heart disease (CHD) test PrecisionCHD were published in the Journal of the American Heart Association. The company noted that PrecisionCHD is a non-invasive and more accessible alternative to current CHD diagnosis tools being in the form of a blood test that uses AI and personalized genetic and epigenetic information to sensitively detect the presence of CHD.
Shares of cardiovascular medicine specialist Cardio Diagnostics (NASDAQ: CDIO ) are skyrocketing on Tuesday following the announcement of a key deal. Specifically, Vizient has awarded Cardio Diagnostics an “Innovation Technology” contract for its artificial intelligence (AI) driven molecular heart disease tests.